-
Acceptance for late breaking oral presentation underscores the
oncology community’s interest in Namodenoson as a potential treatment
for liver cancer -
Can-Fite now preparing for Phase III study of Namodenoson in
patients with advanced liver cancer Child Pugh B 7 cirrhosis with Key
Opinion Leader as Principal Investigator
PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite
BioPharma Ltd. (NYSE MKT: CANF) (TASE:CFBI), a biotechnology company
with a pipeline of proprietary small molecule drugs that address cancer,
liver and inflammatory diseases, announced today that a late-breaking
abstract detailing results from the Company’s recently completed
multicenter Phase II trial in patients with advanced liver cancer has
been accepted for oral presentation at the late-breaking abstract
session of the 54th Annual Meeting of the American Society of
Clinical Oncology (ASCO). The world’s largest clinical cancer research
meeting, ASCO, will take place from May 31 to June 4, 2019 in Chicago,
Illinois.
The abstract titled: “A phase II, randomized, double-blind,
placebo-controlled trial evaluating efficacy and safety of namodenoson
(CF102), an a3 adenosine receptor agonist (A3AR), as a second-line
treatment in patients with Child-Pugh B (CPB) advanced hepatocellular
carcinoma (HCC)”, will be presented in an oral session by Prof. Salomon
Stemmer, Principal Investigator of the Phase II trial.
Oral Abstract Presentation Details
Date:
Tuesday, June 02, 2019
Time: 8:00 am CDT
Oral
abstract session: Developmental Immunotherapy and Tumor Immunobiology
“We consider ASCO’s acceptance of our late breaking oral presentation a
testament to the compelling data coming out of our recently completed
Phase II study of Namodenoson. We believe this reflects the oncology
community’s assessment that our Phase II Namodenoson trial is a
high-impact study with significant relevance in the treatment of liver
cancer,” stated Can-Fite CEO Pnina Fishman.
Can-Fite is currently designing and planning the protocol for a Phase
III study with the support of the world’s leading oncologists and
regulatory experts including Dr. Josep Llovet, Founder and Director of
the Liver Cancer Program and Full Professor of Medicine at the Mount
Sinai School of Medicine, New York, a key opinion leader who will serve
as the Phase III study’s Principal Investigator.
About Namodenoson
Namodenoson is a small orally bioavailable drug that binds with high
affinity and selectivity to the A3 adenosine receptor (A3AR).
Namodenoson is being evaluated as a second line treatment for
hepatocellular carcinoma, with a recently completed Phase II trial and
planned Phase III trial in this indication. The drug is currently in an
ongoing Phase II trial as a treatment for non-alcoholic fatty liver
disease (NAFLD) and non-alcoholic steatohepatitis (NASH). A3AR is highly
expressed in diseased cells whereas low expression is found in normal
cells. This differential effect accounts for the excellent safety
profile of the drug.
About Can-Fite BioPharma Ltd.
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an
advanced clinical stage drug development Company with a platform
technology that is designed to address multi-billion dollar markets in
the treatment of cancer, inflammatory disease and sexual dysfunction.
The Company’s lead drug candidate, Piclidenoson, is currently in Phase
III trials for rheumatoid arthritis and psoriasis. Can-Fite’s liver
cancer drug, Namodenoson, recently completed a Phase II trial for
hepatocellular carcinoma (HCC), the most common form of liver cancer,
and is in a Phase II trial for the treatment of non-alcoholic
steatohepatitis (NASH). Namodenoson has been granted Orphan Drug
Designation in the U.S. and Europe and Fast Track Designation as a
second line treatment for HCC by the U.S. Food and Drug Administration.
Namodenoson has also shown proof of concept to potentially treat other
cancers including colon, prostate, and melanoma. CF602, the Company’s
third drug candidate, has shown efficacy in the treatment of erectile
dysfunction in preclinical studies and the Company is investigating
additional compounds, targeting A3AR, for the treatment of sexual
dysfunction. These drugs have an excellent safety profile with
experience in over 1,000 patients in clinical studies to date. For more
information please visit: www.can-fite.com.
Forward-Looking Statements
This press release may contain forward-looking statements, about
Can-Fite’s expectations, beliefs or intentions regarding, among other
things, market risks and uncertainties, its product development efforts,
business, financial condition, results of operations, strategies or
prospects. In addition, from time to time, Can-Fite or its
representatives have made or may make forward-looking statements, orally
or in writing. Forward-looking statements can be identified by the use
of forward-looking words such as “believe,” “expect,” “intend,” “plan,”
“may,” “should” or “anticipate” or their negatives or other variations
of these words or other comparable words or by the fact that these
statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited
to, various filings made by Can-Fite with the U.S. Securities and
Exchange Commission, press releases or oral statements made by or with
the approval of one of Can-Fite’s authorized executive officers.
Forward-looking statements relate to anticipated or expected events,
activities, trends or results as of the date they are made. Because
forward-looking statements relate to matters that have not yet occurred,
these statements are inherently subject to risks and uncertainties that
could cause Can-Fite’s actual results to differ materially from any
future results expressed or implied by the forward-looking statements.
Many factors could cause Can-Fite’s actual activities or results to
differ materially from the activities and results anticipated in such
forward-looking statements. Factors that could cause our actual results
to differ materially from those expressed or implied in such
forward-looking statements include, but are not limited to: our history
of losses and needs for additional capital to fund our operations and
our inability to obtain additional capital on acceptable terms, or at
all; uncertainties of cash flows and inability to meet working capital
needs; the initiation, timing, progress and results of our preclinical
studies, clinical trials and other product candidate development
efforts; our ability to advance our product candidates into clinical
trials or to successfully complete our preclinical studies or clinical
trials; our receipt of regulatory approvals for our product candidates,
and the timing of other regulatory filings and approvals; the clinical
development, commercialization and market acceptance of our product
candidates; our ability to establish and maintain strategic partnerships
and other corporate collaborations; the implementation of our business
model and strategic plans for our business and product candidates; the
scope of protection we are able to establish and maintain for
intellectual property rights covering our product candidates and our
ability to operate our business without infringing the intellectual
property rights of others; competitive companies, technologies and our
industry; statements as to the impact of the political and security
situation in Israel on our business; and risks and other risk factors
detailed in Can-Fite’s filings with the SEC and in its periodic filings
with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by
economic and other factors beyond its control. Can-Fite does not
undertake any obligation to publicly update these forward-looking
statements, whether as a result of new information, future events or
otherwise.
Contacts
Can-Fite BioPharma
Motti Farbstein
info@canfite.com
+972-3-9241114